Celcuity Inc.
NASDAQ:CELC · NASDAQ Capital Market
-$4.04 today
Vol 1.83M · Avg 1.24M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-176.1%
avg -60.4%
ROIC
-40.8%
avg -42.1%
ROA
-37.9%
avg -39.0%
Analysis
ROA is currently the strongest return metric at -37.9% versus its period average of -39.0%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Brian F. Sullivan | Co-Founder, Chairman & Chief Executive Officer | $945,218.00 | — | 64 | $1.37M | 2.81% |
Lance G. Laing | Co-Founder, Chief Science Officer, Vice President, Secretary & Director | $673,781.00 | — | 64 | $1.25M | 2.57% |
Vicky Hahne | Chief Financial Officer | $598,079.00 | — | 60 | $80,000.00 | 0.16% |
Jodi Sievers | Head of Investor Relations & Corporate Communications | — | — | — | — | — |
Sheri Smith | Acting Head of Clinical Operations | — | — | — | — | — |
Igor Gorbatchevsky | Chief Medical Officer | — | — | — | — | — |
Eldon C. Mayer | Chief Commercial Officer | — | — | 65 | — | — |
Brent Eilefson | General Counsel | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
4
$9.57M
Sells
22
$14.63M
Net Sentiment
$5.06M
Net selling
Most Active
Buller Richard E
12 transactions
1–10 of 26
Analysis
Insiders reported 4 buys worth $9.57M and 22 sells worth $14.63M over the last 12 months. That adds up to net selling of $5.06M. Buller Richard E was the most active insider with 12 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | N/A6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Centessa Pharmaceuticals plc
NASDAQ:CNTA
$6.16B
Apogee Therapeutics, Inc.
NASDAQ:APGE
$5.45B
Legend Biotech Corporation
NASDAQ:LEGN
$5.43B
CG Oncology, Inc. Common stock
NASDAQ:CGON
$5.39B
Travere Therapeutics, Inc.
NASDAQ:TVTX
$5.08B
Xenon Pharmaceuticals Inc.
NASDAQ:XENE
$4.18B
Disc Medicine, Inc.
NASDAQ:IRON
$2.70B
Ultragenyx Pharmaceutical Inc.
NASDAQ:RARE
$2.70B
Zai Lab Limited
NASDAQ:ZLAB
$2.08B
Ascentage Pharma Group International
NASDAQ:AAPG
$403.00M
Who manages CELC?
Celcuity Inc. (CELC) lists 8 active executives. The top listed executive is Vicky Hahne, Chief Financial Officer.
Are CELC insiders buying or selling?
Recent insider activity shows net buying of $45.11M.
Explore More
Continue the stock analysis
Jump to another research area for this company.